ATSN-101
- Generic Name
- ATSN-101
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
ATSN-101 is a adeno-associated virus serotype 5 encoding human retinal guanylate cyclase 1 gene (AAV5-GUCY2D)
- Associated Conditions
- -
- Associated Therapies
- -
Study of Subretinally Injected ATSN-101 Administered in Patients With Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D
Phase 1
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2019-04-18
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Atsena Therapeutics Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT03920007
- Locations
- 🇺🇸
Casey Eye Institute - Oregon Health & Science University, Portland, Oregon, United States
🇺🇸Scheie Eye Institute, University of Pennsylvania, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath